Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company's approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/13/25 | $85,000,000 | Series A Extension |
Chugai Venture Fund Eli Lilly and Company Johnson & Johnson Development Corporation (JJDC) Khosla Ventures RA Capital Management | undisclosed |
